Acadia Pharmaceuticals Inc. Insider Trading

ACAD

Last 12 months

Insiders sold $3.47M and bought nothing on the open market.

77% of the selling was scheduled in advance under 10b5-1 plans. Director James M Daly sold 671K on Nov 10, 2025, 88% of their stake, outside a plan. The last open-market buy by an executive or director was in Mar 2020.

Net open-market

−$3.47M

0 buys · 18 sales

Under a 10b5-1 plan

77%

of the value sold

Insiders who bought / sold

0 / 6

executives and directors

Last open-market buy

Mar 2020

Mar 18, 2020

Get an email when ACAD's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 30	Mark C. Schneyer EVP, Chief Financial Officer	Sold10b5-1 plan	3,321	$20.88	69K	4.4%	Form 4
Aug 5 – 6	Mark C. Schneyer EVP, Chief Financial Officer	Sold10b5-1 plan 3 parts	20,141	$29.16 average	587K	23%	Form 4
Jul 30	Elizabeth H.z. Thompson EVP, Head of Research & Dev	Sold10b5-1 plan 2 parts	16,558	$26.13 average	433K	47%	Form 4
Jun 26	James Kihara Principal Accounting Officer	Sold10b5-1 plan	11,421	$26.08	298K	47%	Form 4
May 26	James Kihara Principal Accounting Officer	SoldNo plan	5,401	$21.18	114K	18%	Form 4
May 4	Mark C. Schneyer EVP, Chief Financial Officer	Sold10b5-1 plan	3,506	$21.79	76K	5.0%	Form 4
May 4	James Kihara Principal Accounting Officer	Sold10b5-1 plan	1,332	$21.79	29K	4.4%	Form 4
Apr 7	Mark C. Schneyer EVP, Chief Financial Officer	Sold10b5-1 plan	2,709	$22.20	60K	4.1%	Form 4
Apr 7	James Kihara Principal Accounting Officer	Sold10b5-1 plan	1,030	$22.20	23K	3.6%	Form 4
Mar 25 – 26	Mark C. Schneyer EVP, Chief Financial Officer	Sold10b5-1 plan 3 parts	7,385	$21.55 average	159K	11%	Form 4
Mar 25 – 26	James Kihara Principal Accounting Officer	Sold10b5-1 plan 3 parts	1,942	$21.57 average	42K	6.7%	Form 4
Mar 25	Elizabeth H.z. Thompson EVP, Head of Research & Dev	Sold10b5-1 plan	3,435	$21.47	74K	51%	Form 4
Mar 25	Adams Catherine Owen Chief Executive Officer	Sold10b5-1 plan	11,641	$21.47	250K	44%	Form 4
Mar 25	Jennifer J Rhodes EVP, Chief Legal Officer, Sec	Sold10b5-1 plan	3,844	$21.47	83K	25%	Form 4
Feb 9	Jennifer J Rhodes EVP, Chief Legal Officer, Sec	Sold10b5-1 plan	6,950	$23.38	162K	48%	Form 4
Nov 18, 2025	Mark C. Schneyer EVP, Chief Financial Officer	Sold10b5-1 plan	10,262	$23.69	243K	16%	Form 4
Nov 18, 2025	James Kihara Principal Accounting Officer	Sold10b5-1 plan	4,084	$23.69	97K	14%	Form 4
Nov 10, 2025	James M Daly Director	SoldNo plan	30,000	$22.37	671K	88%	Form 4
Sep 15, 2025	Mark C. Schneyer EVP, Chief Financial Officer	Sold10b5-1 plan	3,498	$23.65	83K	7.5%	Form 4
Sep 2, 2025	Elizabeth A. Garofalo Director	SoldNo plan	1,600	$25.98	42K	5.9%	Form 4
Aug 18, 2025	Mark C. Schneyer EVP, Chief Financial Officer	Sold10b5-1 plan	22,000	$25.18	554K	35%	Form 4
Jun 4, 2025	Laura Brege Director	SoldNo plan	14,446	$21.78	315K	49%	Form 4
May 16, 2025	James Kihara Principal Accounting Officer	Sold10b5-1 plan 2 parts	4,000	$22.50 average	90K	16%	Form 4
May 16, 2025	Mark C. Schneyer EVP, Chief Financial Officer	Sold10b5-1 plan	2,000	$25.00	50K	3.1%	Form 4
May 2, 2025	James Kihara Principal Accounting Officer	Sold10b5-1 plan	1,327	$14.60	19K	5.3%	Form 4
May 2, 2025	Mark C. Schneyer EVP, Chief Financial Officer	Sold10b5-1 plan	3,498	$14.60	51K	5.3%	Form 4
Apr 8, 2025	Mark C. Schneyer EVP, Chief Financial Officer	Sold10b5-1 plan	2,708	$14.82	40K	4.4%	Form 4
Apr 8, 2025	James Kihara Principal Accounting Officer	Sold10b5-1 plan	1,028	$14.82	15K	4.4%	Form 4
Mar 26, 2025	James Kihara Principal Accounting Officer	Sold10b5-1 plan	1,095	$17.05	19K	4.9%	Form 4
Mar 26, 2025	Mark C. Schneyer EVP, Chief Financial Officer	Sold10b5-1 plan	3,171	$17.05	54K	5.3%	Form 4
Mar 5, 2025	Elizabeth A. Garofalo Director	SoldNo plan	4,919	$18.23	90K	22%	Form 4
Feb 24, 2025	James Kihara Principal Accounting Officer	Sold10b5-1 plan	475	$19.96	9K	2.3%	Form 4
Feb 24, 2025	Mark C. Schneyer EVP, Chief Financial Officer	Sold10b5-1 plan	773	$19.96	15K	1.4%	Form 4
Nov 19, 2024	Brendan Teehan EVP, COO, Head of Commercial	Sold10b5-1 plan	10,329	$16.81	174K	14%	Form 4
Nov 19, 2024	James Kihara Principal Accounting Officer	Sold10b5-1 plan	4,073	$16.81	68K	17%	Form 4
Nov 19, 2024	Mark C. Schneyer EVP, Chief Financial Officer	Sold10b5-1 plan	10,259	$16.81	172K	16%	Form 4

Oct 3010b5-1 plan
Mark C. Schneyer
EVP, Chief Financial Officer · sold 3,321 at $20.88
69K
4.4% of stake
Aug 5 – 610b5-1 plan
Mark C. Schneyer
EVP, Chief Financial Officer · sold 20,141 at avg $29.16
587K
23% of stake
Jul 3010b5-1 plan
Elizabeth H.z. Thompson
EVP, Head of Research & Dev · sold 16,558 at avg $26.13
433K
47% of stake
Jun 2610b5-1 plan
James Kihara
Principal Accounting Officer · sold 11,421 at $26.08
298K
47% of stake
May 26No plan
James Kihara
Principal Accounting Officer · sold 5,401 at $21.18
114K
18% of stake
May 410b5-1 plan
Mark C. Schneyer
EVP, Chief Financial Officer · sold 3,506 at $21.79
76K
5.0% of stake
May 410b5-1 plan
James Kihara
Principal Accounting Officer · sold 1,332 at $21.79
29K
4.4% of stake
Apr 710b5-1 plan
Mark C. Schneyer
EVP, Chief Financial Officer · sold 2,709 at $22.20
60K
4.1% of stake
Apr 710b5-1 plan
James Kihara
Principal Accounting Officer · sold 1,030 at $22.20
23K
3.6% of stake
Mar 25 – 2610b5-1 plan
Mark C. Schneyer
EVP, Chief Financial Officer · sold 7,385 at avg $21.55
159K
11% of stake
Mar 25 – 2610b5-1 plan
James Kihara
Principal Accounting Officer · sold 1,942 at avg $21.57
42K
6.7% of stake
Mar 2510b5-1 plan
Elizabeth H.z. Thompson
EVP, Head of Research & Dev · sold 3,435 at $21.47
74K
51% of stake
Mar 2510b5-1 plan
Adams Catherine Owen
Chief Executive Officer · sold 11,641 at $21.47
250K
44% of stake
Mar 2510b5-1 plan
Jennifer J Rhodes
EVP, Chief Legal Officer, Sec · sold 3,844 at $21.47
83K
25% of stake
Feb 910b5-1 plan
Jennifer J Rhodes
EVP, Chief Legal Officer, Sec · sold 6,950 at $23.38
162K
48% of stake
Nov 18, 202510b5-1 plan
Mark C. Schneyer
EVP, Chief Financial Officer · sold 10,262 at $23.69
243K
16% of stake
Nov 18, 202510b5-1 plan
James Kihara
Principal Accounting Officer · sold 4,084 at $23.69
97K
14% of stake
Nov 10, 2025No plan
James M Daly
Director · sold 30,000 at $22.37
671K
88% of stake
Sep 15, 202510b5-1 plan
Mark C. Schneyer
EVP, Chief Financial Officer · sold 3,498 at $23.65
83K
7.5% of stake
Sep 2, 2025No plan
Elizabeth A. Garofalo
Director · sold 1,600 at $25.98
42K
5.9% of stake
Aug 18, 202510b5-1 plan
Mark C. Schneyer
EVP, Chief Financial Officer · sold 22,000 at $25.18
554K
35% of stake
Jun 4, 2025No plan
Laura Brege
Director · sold 14,446 at $21.78
315K
49% of stake
May 16, 202510b5-1 plan
James Kihara
Principal Accounting Officer · sold 4,000 at avg $22.50
90K
16% of stake
May 16, 202510b5-1 plan
Mark C. Schneyer
EVP, Chief Financial Officer · sold 2,000 at $25.00
50K
3.1% of stake
May 2, 202510b5-1 plan
James Kihara
Principal Accounting Officer · sold 1,327 at $14.60
19K
5.3% of stake
May 2, 202510b5-1 plan
Mark C. Schneyer
EVP, Chief Financial Officer · sold 3,498 at $14.60
51K
5.3% of stake
Apr 8, 202510b5-1 plan
Mark C. Schneyer
EVP, Chief Financial Officer · sold 2,708 at $14.82
40K
4.4% of stake
Apr 8, 202510b5-1 plan
James Kihara
Principal Accounting Officer · sold 1,028 at $14.82
15K
4.4% of stake
Mar 26, 202510b5-1 plan
James Kihara
Principal Accounting Officer · sold 1,095 at $17.05
19K
4.9% of stake
Mar 26, 202510b5-1 plan
Mark C. Schneyer
EVP, Chief Financial Officer · sold 3,171 at $17.05
54K
5.3% of stake
Mar 5, 2025No plan
Elizabeth A. Garofalo
Director · sold 4,919 at $18.23
90K
22% of stake
Feb 24, 202510b5-1 plan
James Kihara
Principal Accounting Officer · sold 475 at $19.96
9K
2.3% of stake
Feb 24, 202510b5-1 plan
Mark C. Schneyer
EVP, Chief Financial Officer · sold 773 at $19.96
15K
1.4% of stake
Nov 19, 202410b5-1 plan
Brendan Teehan
EVP, COO, Head of Commercial · sold 10,329 at $16.81
174K
14% of stake
Nov 19, 202410b5-1 plan
James Kihara
Principal Accounting Officer · sold 4,073 at $16.81
68K
17% of stake
Nov 19, 202410b5-1 plan
Mark C. Schneyer
EVP, Chief Financial Officer · sold 10,259 at $16.81
172K
16% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ACAD, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ACAD

CompareIntrinsic value

APLSApellis Pharmaceuticals, Inc.

$3.10+3.29%83

PBHPrestige Consumer Healthcare Inc.

$53.28+7.55%48

PTCTPTC Therapeutics, Inc.

$68.97+1.25%65

MDGLMadrigal Pharmaceuticals, Inc.

$400.67+1.10%10

HRMYHarmony Biosciences Holdings, Inc.

$34.42-7.04%82

INDVIndivior Pharmaceuticals, Inc.

$36.28+2.57%80

ANIPAni Pharmaceuticals Inc.

$72.89+0.84%85

IONSIonis Pharmaceuticals, Inc.

$40.15-0.67%39

Held by ETFs

ACAD is in 96 US ETFs. The largest of them, with ACAD's weight in each:

Spot a number that looks wrong? Check it in ACAD's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ACAD

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.